The pharmaceutical industry has monetised this through aggressive marketing of medication as the solution to a healthier lifestyle, shifting the focus away from dietary or lifestyle changes
Exploring this question necessitates a careful examination of existing pharmacological data, clinical trials, and mechanistic studies to ascertain whether Berberines effects truly parallel those mediated by GLP-1 receptor agonists or whether the analogy may oversimplify and misrepresent the distinct biological pathways involved
Some suggest the medications may reduce binge-eating episodes in patients with BED or bulimia nervosa, but sample sizes were limited, follow-up periods were short, and long-term effects remain unknown
According to Table 3,in crude model of binary regression analysis, individuals in upper median group of GHGE had 13% and 11% higher risk of overweight/obese or underweight, as well as high WHR, with of OR, respectively (OR: 1.13, 95% CI: 0.961.32, P = 0.122
The concern about starting too early is legitimate but applies primarily to traditional hyaluronic acid fillers, not biostimulators
Recently, the STEP-HFpEF trial enrolled 529 non-diabetic patients with HFpEF and obesity, who were randomly assigned to receive either once-weekly semaglutide (2.4 mg) or placebo for 52 weeks
